Indications for Platelet Transfusion in Chronic Liver Disease

Understanding Coagulation in Chronic Liver Disease

Chronic liver disease presents a "rebalanced" hemostatic state despite apparent laboratory abnormalities, with both reduced procoagulant factors and reduced anticoagulants 2, 3
Traditional coagulation tests like INR poorly predict bleeding risk in liver disease patients and don't reflect the overall hemostatic balance 1, 4
Low platelet counts in chronic liver disease often reflect disease severity and portal hypertension rather than being an independent risk factor for bleeding 5

Platelet transfusion is indicated for active bleeding when platelet count is <50 x 10^9/L 6, 7
For decompensated liver disease with consumptive coagulopathy, platelet transfusion may be needed with counts <30 x 10^9/L 6
For high-risk procedures, maintain platelet count >50 x 10^9/L 6, 8
Less stringent thresholds (platelets ≥25 x 10^9/L) may be appropriate for some procedures like percutaneous liver biopsy 2, 3

Platelet transfusions may increase portal pressure and carry risks of transfusion-associated circulatory overload, transfusion-related acute lung injury, infection transmission, and alloimmunization 2, 6
Platelet increments may be poor and short-lived in patients with portal hypertension 1, 4
Studies show that prophylactic platelet transfusions have not demonstrated significant reduction in procedural bleeding complications 5

TPO-RAs (lusutrombopag, avatrombopag) are FDA-approved alternatives to platelet transfusion for patients with chronic liver disease and severe thrombocytopenia (<50 x 10^9/L) undergoing planned procedures 3, 4
Viscoelastic assays (thromboelastography) can better assess overall hemostatic status in liver disease patients 6, 7
A thromboelastogram-guided transfusion strategy has been shown to significantly reduce blood product use without increasing bleeding complications 6

Avoid unnecessary prophylactic platelet transfusions based solely on laboratory values 5, 8
Don't rely exclusively on INR or platelet count to assess bleeding risk 2, 3
Consider vitamin K administration in patients with increased INR, which may partly reflect vitamin K deficiency 6, 7
Recognize that platelet transfusions may paradoxically increase bleeding risk by increasing portal pressure and intravascular volume 2, 5
For patients with decompensated cirrhosis and acute kidney injury, be aware of increased bleeding risk after procedures 6